Introduction
============

Oxidative stress and coronary artery disease (CAD) are thought to be closely linked ([@b1-br-0-0-1071]--[@b3-br-0-0-1071]). In the era of trans-radial approach in coronary angiography (CA), where peri-procedural bleeding is minimized, new expectations for reduced incidence of acute kidney injury arise ([@b4-br-0-0-1071],[@b5-br-0-0-1071]). It is possible that the site of vascular access and reduced bleeding contributes to reduced incidence of contrast-induced nephropathy (CIN) in radial CA, as was evident in the analysis of the large retrospective Blue Cross Blue Shield of Michigan Cardiovascular Consortium database ([@b6-br-0-0-1071]).

However, the importance of additional parameters, such as peri-procedural oxidative stress variations and their associations with early indications of CIN in radial catheterization deserve further exploring. Oxidative stress is linked both to CAD and acute coronary syndromes and at the same time is one of the core features of CIN ([@b7-br-0-0-1071]). Oxidative stress variations occurring early post-contrast administration and their associations with the contrast volume used may be of interest both from a pathophysiological and clinical perspective. At the same time differences in oxidative stress and occurrence of CIN in patients receiving intravenous contrast media compared to patients with arterial administration of contrast are postulated ([@b8-br-0-0-1071]). To some extent dose-toxicity relationship following intravenous administration at usual diagnostic doses seems not to apply ([@b9-br-0-0-1071]).

Early recognition of contrast-induced acute kidney injury is of high clinical importance especially with the short hospitalization time currently employed for patients scheduled for CA or intervention. Previously, early renal dysfunction was reported to occur only a few hours post-CA ([@b10-br-0-0-1071],[@b11-br-0-0-1071]).

The aim of the present study was to determine the early changes in oxidative status of CAD patients submitted to trans-radial angiography and their association with early signs of CIN compared to the relevant oxidative status of age-sex matched patients submitted to intravenous contrast administration in the setting of computed tomography (CT).

Materials and methods
=====================

### Participants

Twenty ischemic patients (CAD group) who were diagnosed with stable CAD and submitted to scheduled CA at the Red Cross General Hospital of Athens were enrolled in the present study. In 4 patients single vessel percutaneous coronary intervention (PCI) was performed. Seventeen sex-matched patients not-diagnosed with ischemia and undergoing CT for myoskeletal reasons at the Amalia Fleming General Hospital (Athens, Greece), were recruited as the control group. The study population had a statistically similar profile concerning underlying pathologies and a similar biochemical and metabolic profile ([Table I](#tI-br-0-0-1071){ref-type="table"}). Exclusion criteria included untreated peripheral vascular disease, cognitive impairment, acute systematic or infectious diseases or fever, acute pericarditis or myocarditis, new onset atrial fibrillation, on-going maintenance dialysis or impaired kidney function, neoplastic diseases, severe liver dysfunction, major surgery, chronic inflammatory diseases and systemic lupus erythematosus. Patients suffering from severe life-threatening injuries to other organs were also excluded. Written informed consent was obtained from all the participants. The research Ethics Committees of the involved institutes approved the procedures. The Declaration of Helsinki (2000) and the applicable national standards as they relate to the involvement of human subjects in research were enforced. The present study was conducted in the framework of the master theses of DL and XP for the MSc course of Toxicology at the University of Thessaly.

The patients were administered with Ultravist sol 62.34% (30% iodine, iopromide) for contrast medium (CM), 50--200 ml intra-arterially for the CAD group and 50--100 ml intravenously for the control group.

CIN is defined as the impairment of renal function manifested by an increase of creatinine of 0.5 mg/dl or 25% from baseline within 48--72 h post-contrast administration ([@b7-br-0-0-1071],[@b11-br-0-0-1071],[@b12-br-0-0-1071]). In the present study, early CIN was defined as fulfilling the CIN criteria definition at 6--10 h post-contrast administration. Early renal dysfunction was reported in a previous study as early as 12--18 h post-contrast administration ([@b11-br-0-0-1071]).

### Data collection and analyses

Venous blood samples were drawn from the subjects upon hospital admission (baseline values, fasting venous samples), 1 h after the CM administration and at the time the patients were discharged (4--6 h for CAD patients and 5--10 h for the control group), for the evaluation of the general metabolic profile, as well as for the markers of oxidative stress.

In serum samples separated from the total blood, general metabolic parameters were assayed using enzymatic commercial kits and the COBAS INTEGRA 800 automated system by Roche Diagnostics Corp (Indianapolis, IN, USA) using all relevant diagnostic reagents. Serum insulin levels were measured using a human immunoradiometric assay diagnostic kit (KIP1251; DIAsource ImmunoAssays S.A., Belgium). The fasting insulin resistance index (FIRI), which is derived from fasting plasma insulin and glucose levels and has been validated against the hyperinsulinemic-euglycemic clamp ([@b13-br-0-0-1071]), was used in the present study as an empirical insulin resistance index. The following formula was used: FIRI = fasting glucose (mmol/l) × fasting insulin (mU/l)/25 ([@b14-br-0-0-1071],[@b15-br-0-0-1071]).

Plasma samples and suspension of erythrocytes lysates were frozen and kept at −80°C for one month. All the samples (CAD and controls) were analyzed at the same time for the markers of oxidative stress.

Reduced glutathione (GSH), catalase, protein carbonyls, thiobarbituric acid reactive species (TBARS) and total anti-oxidant capacity (TAC) were determined as previously described ([@b16-br-0-0-1071]).

### Statistical analysis

Results are presented as mean ± standard deviation (SD). Statistical analyses were performed using SPSS 22.0 software (IBM Corp., Armonk, NY, USA). Significant differences between means for the same parameters were investigated using repeated measures ANOVA with Bonferroni post-hoc test and paired t-test analyses. Independent t-tests were used to compare mean values between groups. Pearson\'s and Spearman\'s correlations and linear regression analysis were conducted to investigate associations between various variables. Differences between categorical variables were assessed by the Chi-square test. Multiple linear regression analyses were performed to evaluate the influence of various biochemical parameters at baseline (age, body mass index, FIRI, Pt/L, N/L, haematocrit, haemoglobin, cholesterol, HDL, LDL, triglycerides, creatinine, urea, uric acid, TAC, GSH, TBARS, carbonyls, catalase and chronic medication used), on the elevation of creatinine after CM administration. P≤0.05 was considered to indicate a statistically significant difference.

Results
=======

### Demographics and baseline values

Baseline values for all the parameters screened are summarised in [Table I](#tI-br-0-0-1071){ref-type="table"}. The oxidative status of CAD patients undergoing scheduled CA was significantly different from the control group. Although the TAC was practically similar between the study groups, it seems that in CAD patients, lipid peroxidation as depicted by TBARS, was 2-fold lower compared to controls, at the expense of protein oxidation, as carbonyls levels were 35% higher in CAD patients. GSH and catalase were both decreased in CAD patients possibly due to impaired oxygenation. More specifically, in CAD patients, GSH was almost 4-fold lower than the control group, while catalase was only 10% decreased.

### Development of CIN

In 4 of 20 CAD patients CIN was developed early after CM intra-arterial administration during CA. The profile of those patients is presented in [Table II](#tII-br-0-0-1071){ref-type="table"}. Creatinine increase varied from 36.0 to 77.8% in 4--6 h after CM administration. A constant 16% (P=0.039) increase in TAC, at all time intervals, was observed. The most pronounced increase in oxidative stress markers was found for GSH (41.2--277% at 1 h, P\<0.01), which continued to rise even at 4--6 h after CM administration and reached 10-fold higher values compared to baseline for two individuals. Lipid peroxidation increased with time in 3 of 4 CAD patients that developed early CIN after CM administration (1.49--20.5% at 1 h, P=0.06; 12.5--64.5% at 4--6 h, P=0.022). Higher (approximately 6.84%) levels were also observed for catalase at 1 h after CM administration, which returned to baseline 2--4 h later. Carbonyls, resulting from protein oxidation, decreased up to 56% in one individual 1 h after CM administration, while 2--4 h later the decrease continued (3.83--64.8%, P=0.045).

In multiple logistic regression analysis, only the creatinine levels at baseline influenced the frequency of early CIN development (β =0.36, 95% CI: 0.285--0.438, P=0.01). More specifically, early CIN patients had 11.7% lower creatinine levels than the rest of the CAD group. In addition, the decreased (61%) GSH baseline levels exhibited a nearly significant effect (P=0.067) on the frequency of early CIN development. However the intra-individual variation was very high.

The observed differences in oxidative stress markers between CAD patients who presented evidence of early CIN and the rest of the CAD group at the various time points are shown in [Fig 1](#f1-br-0-0-1071){ref-type="fig"}.

Effect of CM administration on renal function and oxidative stress markers. In our study, the renal function and the oxidative status of the patients after CM administration, excluding those that have developed early CIN, are described in [Table III](#tIII-br-0-0-1071){ref-type="table"}. CM administration, either intra-arterially or intravenously, did not significantly affect urea, which was actually decreased, probably due to usual instructed hydration of the patients by the attending physicians prior or after CM administration. Average creatinine, which was almost 20% lower in the CAD group, slightly increased after 4--6 h. By contrast, in the control group, which consisted of patients undergoing CT for myoskeletal reasons, creatinine was decreased up to 21% after 5--10 h. The observed differences in creatinine profile could be due to different hydration instructions given to the two groups of patients: CAD patients are usually hydrated as a pre-conditioning process a couple of days prior to CA, whereas patients undergoing CT are usually advised to intensively hydrate after the examination.

Regarding oxidative stress markers, in CAD patients TAC increased almost 10% after the CA. GSH and lipid peroxidation gradually increased after CM administration and reached 180% (P\<0.001) and 20% (P=0.021) after 4--6 h, respectively. Protein oxidation significantly decreased (approximately 30%, P=0.021) with time after CM administration and the same trend was observed for catalase (6%, P=0.013). In the control group, where intravenous CM administration was used, a more subtle effect in the oxidative stress status was observed, with TAC remaining practically unchanged. The same pattern was followed, however, with gradual non-significant increase in GSH (5.23--11.5%) and increase in TBARS levels (approximately 7%).

Discussion
==========

Reactive oxygen species (ROS) overproduction is thought to be closely linked to cardiovascular disease and its complications. In a previous study in both stable CAD patients and acute coronary syndrome patients, plasma levels of aminothiols cystine and glutathione were associated with the risk of future death independently and additive to inflammation assessed by hs-CRP ([@b1-br-0-0-1071]). ROS generation is attributed to vascular enzymatic and non-enzymatic processes. Enzymatic processes include the uncoupling of nitric oxide synthase (NOS), nicotinamide adenine dinucleotide phosphate oxidase, and xanthine oxidase, while main non-enzymatic ROS sources are the mitochondria, where ROS are produced at complex I and III of the respiratory chain ([@b17-br-0-0-1071]). Baseline oxidative stress values of the CAD patients presented evidence of a distinct pattern of oxidative stress variations. Lipid peroxidation was significantly reduced and protein oxidation was augmented compared to age-sex matched controls, while anti-oxidant defences of CAD patients represented mainly by glutathione reduction despite the practically unchanged TAC levels. Weinbrenner *et al* showed that while lipid peroxidation did not differ significantly between CAD patients and controls, increased oxidized LDL and glutathione peroxide levels characterized CAD patients ([@b18-br-0-0-1071]). Moreover, similar to our observations, Li *et al* found that lipid peroxidation was significantly elevataed in CAD patients compared to controls prior to the initiation of statin treatment ([@b19-br-0-0-1071]) and returned to similar to control levels post-treatment.

In the setting of CA and PCI, oxidative stress emerges as a dangerous and often underestimated parameter for CIN provocation, while in clinical studies the first attempts of antioxidant supplementation prior or after CA did not present the expected results in CIN amelioration ([@b7-br-0-0-1071],[@b20-br-0-0-1071]). Few studies have examined the changing environment regarding oxidative stress following CA and related interventions ([@b21-br-0-0-1071],[@b22-br-0-0-1071]), where femoral assess was used. In the era of growing use of radial assess in CA, a changing post-procedural oxidative profile compared to femoral assess was assumed. In the present study, where radial assess was applied exclusively, early variations in oxidative stress markers were found. In the first hour post-CA in CAD patients who did not develop CIN, TAC significantly increased and carbonyls significantly decreased, while in 4--6 h GSH and TBARS significantly increased and catalase significantly decreased. In the study of Kochiadakis *et al* total peroxides significantly increased 1 day post-stent implantation only in patients receiving bare-metal stents compared to patients receiving sirolimus-eluting stents ([@b21-br-0-0-1071]) and the increase in total peroxide correlated with in-stent late lumen loss. In elderly patients with stable angina submitted to CA and PCI via the femoral route, Szewczyk-Golec *et al* found no differences in antioxidant enzymes and malondialdehyde levels ([@b22-br-0-0-1071]). However, Ciçek *et al* reported significant increases in TAC immediately after PCI via the femoral route ([@b23-br-0-0-1071]).

CIN post-CA is associated with prolonged hospitalization and in-hospital and long-term mortality ([@b24-br-0-0-1071],[@b25-br-0-0-1071]). In an attempt to reduce the incidence of CIN with a single injection of reduced glutathione prior to CA, Wang *et al* ([@b20-br-0-0-1071]) identified that 24-h post-procedure TAC was increased, while MDA levels were reduced. In the present study, TBARS levels increased 4--6 h post-CA. In the setting of primary PCI for myocardial infarction via the femoral route, Börekçi *et al* found that patients who developed CIN have lower baseline values of total anti-oxidant status and higher oxidative stress index and total oxidant status compared to non CIN patients ([@b26-br-0-0-1071]). In the present study, baseline values of TAC, catalase and TBARS were similar between the early CIN and non-CIN groups, while significant differences were found in GSH and carbonyl levels that were both lower in the early CIN group. Using multivariate logistic regression analysis, Börekçi *et al* ([@b26-br-0-0-1071]) found that oxidative stress index and contrast volume used were independent predictors of CIN, while in the present study only baseline creatinine values predicted early CIN.

Ribichini *et al* showed that a creatinine increase 12 h post-contrast media administration is the most sensitive and specific risk factor for regular CIN prediction ([@b27-br-0-0-1071]). Burchardt *et al*, however, showed that 12--18 h post-CA an increase in creatinine level or a decrease in creatinine clearance and a reduction in glomerular filtration rate involved up to 28% of patients ([@b10-br-0-0-1071]). In the present study, a high incidence of early CIN was observed only 6 h post-CA. Low absolute baseline creatinine values due to excess hydration or subclinical renal dysfunction could account for the rapid 25% increase in absolute creatinine values accounting for early CIN in the patient subgroup in the present study.

In the present study of exclusive radial assess, distinct patterns of oxidative stress modifications occurred early post-CA with various differences to previous studies of femoral assess to CA. Predominance of GSH reduction in the baseline values of early CIN patients albeit not relevant in regression analysis needs further exploring. The rapid increase of GSH in all the patients submitted to radial CA in an environment of steady TAC values similar to the control group probably indicates a not too unfavorable environment with respect to oxidative stress in radial CA that allows the timely activation of patients\' antioxidant defenses. At the same time, lipid peroxidation depicted by TBARS presented a mild increase, suggesting a subtle distortion of lipid cell components as membranes.

In conclusion, early oxidative stress changes occur in bloodstream of patients submitted to radial CA with relative mild profile, sufficient though to mobilize patient antioxidant defenses.
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![Oxidative stress markers in CAD patients who presented evidence of early CIN and the rest of the CAD group at various time points post-coronary angiography. (A) GSH, (B) TAC, (C) TBARS, (D) Catalase, and (E) carbonyls. GSH, reduced glutathione; TAC, total anti-oxidant capacity; TBARS, thiobarbituric acid reactive species; CAD, coronary artery disease; CIN, contrast-induced nephropathy.](br-08-05-0417-g00){#f1-br-0-0-1071}

###### 

Demographic characteristics and baseline biochemical parameters of the study population.

  Parameters                      CAD patients undergoing CA   Control group: No CAD patients undergoing CT   P-value
  ------------------------------- ---------------------------- ---------------------------------------------- ---------
  No.                             20                           17                                             
  Age (years)                     64.8±10.4                    71.9±14.3 (P=0.089)                            
  Sex                                                                                                         
    Male                          13                           12                                             
    Female                        7                            5                                              
  Weight (kg)                     81.5±10.1                    72.4±9.39                                      0.009
  Height (cm)                     169±8.15                     164±4.56                                       0.569
  BMI                             28.6±2.89                    25.6±6.32                                      0.013
  Smoking                         13 (3 ex-smokers)            9                                              0.569
  Chronic treatment                                                                                           
    Anti-platelets                13                           10                                             
    Anti-coagulants               4                            4                                              
    β-blockers                    12                           10                                             
    Ca channel blockers           7                            9                                              
    ACE inhibitors                9                            6                                              
    Diuretics                     8                            8                                              
    Statins - antilipidemics      14                           13                                             
    Anti-diabetics                3                            3                                              
  Laboratory data                                                                                             
    Hematocrit                    38.3±4.21                    39.1±6.58                                      0.183
    Hemoglobin                    12.7±1.85                    13.1±1.15                                      0.325
    P/L                           92.4±23.3                    93.4±26.6                                      0.111
    N/L                           2.38±0.714                   2.33±0.324                                     0.563
    Glucose (mg/dl)               115±26.9                     126±46.1                                       0.842
    Insulin                       16.3±11.9                    12.4±8.41                                      0.278
    FIRI                          73.6±46.9                    76.4±63.0 (20.4--180)                          0.456
    Creatinine (mg/dl)            0.796±0.217                  1.06±0.190                                     0.001
    Urea (mg/dl)                  38.8±13.4                    42.8±23.2                                      0.518
    Uric acid (mg/dl)             5.59±1.67                    4.99±2.43                                      0.509
    Cholesterol (mg/dl)           188±49.7                     194±59.7                                       0.183
    Triglycerides (mg/dl)         132±45.1                     145±45.1                                       0.286
    HDL (mg/dl)                   46.3±14.8                    56.3±34.8                                      0.100
    LDL (mg/dl)                   106±32.6                     116±44.6                                       0.177
    K (mmol/l)                    4.44±0.562                   4.65±0.666                                     0.683
    Na (mmol/l)                   138±2.70                     135±6.70                                       0.983
    Albumin (g/dl)                41.0±3.92                    33.0±3.92                                      0.226
    Total protein (g/dl)          65.6±5.61                    60.4±1.11                                      0.345
    SGOT (IU/l)                   20.5±6.59                    28.5±2.49                                      0555
    SGPT (IU/l)                   19.6±9.44                    29.5±10.4                                      0.145
    γ-GT (IU/l)                   13.4±2.23                    16.4±5.23                                      0.445
    LDH (IU/l)                    194±56.9                     204±69.9                                       0.256
    CPK (U/l)                     121±154 (38--596)            111±16.3                                       0.888
  Oxidative stress markers                                                                                    
    GSH (µmol/g Hb)               0.516±0.482                  1.91±0.807                                     \<0.001
    TAC (mmol DPPH/L plasma)      0.894±0.128                  0.956±0.150                                    0.183
    TBARS (µmol/l)                3.66±1.31                    7.32±1.34                                      \<0.001
    Catalase (U/mg Hb)            174±30.1                     192±67.8                                       0.301
    Carbonyls (nmol/mg protein)   1.22±0.427                   0.793±0.141                                    \<0.001

Data presented as mean ± standard deviation (SD). Statistical comparison is made between groups 1 and 2.

P\<0.05

P\<0.01. ACE, angiotensin converting enzyme; BMI, body mass index, BMI=weight (kg)/(height)^2^ (m^2^); CAD, coronary artery disease; CT, computed tomography; CA, coronary angiography; ARB, angiotensin receptor blockers; N/L, neutrophils to lymphocytes ratio; P/L, platelets to lymphocytes ratio; CRP, C-reactive protein; FIRI, (glucose × insulin)/25; TAC, total anti-oxidant activity; GSH, glutathione; TBARS, thio-barbituric acid reactive species.

###### 

Demographic, biochemical and redox profile of CAD patients that have developed early CIN.

  Parameters                    Patient 1   Patient 2   Patient 3   Patient 4
  ----------------------------- ----------- ----------- ----------- -----------
  Age (years)                   67          76          80          55
  Sex                           Male        Female      Female      Male
  Weight (Kg)                   74          70          73          98
  Height (cm)                   175         165         150         180
  BMI                           24.2        25.7        32.4        30.2
  Smoking                       Ex-smoker   No          No          Yes
  Chronic treatment                                                 
    Anti-platelets              Yes         Yes         Yes         Yes
    Anti-coagulants             --          --          --          --
    β-blockers                  Yes         Yes         --          --
    Ca channel blockers         --          --          --          Yes
    ACE inhibitors              Yes         Yes         Yes         --
    Diuretics                   --          Yes         --          --
    Statins - anti-lipidemics   Yes         Yes         Yes         Yes
    Anti-diabetics              --          --          --          Yes
  Laboratory data                                                   
    Hematocrit                  37.640.5    38.2        --          
    Hemoglobin                  12.313.3    12.5        --          
    P/L                         11672.4     119         --          
    N/L                         2.94        1.39        2.79        --
    Glucose (mg/dl)             81          106         148         85
    Insulin                     20.2        18.5        21.6        61
    FIRI                        65.4        78.4        128         207
  Creatinine (mg/dl)                                                
    t=0                         0.59        0.45        0.50        0.68
    t=2 h                       0.89        0.68        0.65        0.98
    t=4--6 h                    0.85        0.80        0.68        1.06
  Urea (mg/dl)                                                      
    t=0                         31          30          55          16
    t=2 h                       42          27          57          25
    t=4--6 h                    40          30          49          19
    Uric acid (mg/dl)           5.40        4.10        3.90        4.40
    Cholesterol (mg/dl)         148         194         182         132
    Triglycerides (mg/dl)       132         140         122         152
    HDL (mg/dl)                 42          39          56          40
    LDL (mg/dl)                 100         116         108         122
    K (mmol/l)                  4.9         4.0         4.4         --
    Na (mmol/l)                 138         136         137         --
    Albumin (g/dl)              44          36          --          --
    Total protein (g/dl)        65.2        60.4        --          --
    SGOT (IU/l)                 19          18          14          --
    SGPT (IU/l)                 20          13          11          --
    γ-GT (IU/l)                 --          16          --          --
    LDH (IU/l)                  --          218         --          --
    CPK (U/l)                   59          135         --          --
  Oxidative stress markers                                          
  GSH (µmol/g Hb)                                                   
    t=0                         0.663       0.145       0.061       0.045
    t=2 h                       1.005       0.248       0.086       0.170
    t=4--6 h                    2.626       0.270       1.23        1.48
  TAC (mmol DPPH/L plasma)                                          
    t=0                         0.919       0.757       0.791       0.961
    t=2 h                       0.992       0.828       1.08        1.07
    t=4--6 h                    1.02        0.897       1.05        1.00
  TBARS (µmol/l)                                                    
    t=0                         5.86        3.77        3.82        2.75
    t=2 h                       5.75        2.74        4.62        3.34
    t=4--6 h                    9.85        2.96        5.64        3.04
  Catalase (U/mg Hb)                                                
    t=0                         154         125         217         199
    t=2 h                       160         135         189         218
    t=4--6 h                    149         128         220         214
  Carbonyls (nmol/mg protein)                                       
    t=0                         0.826       1.02        0.779       1.64
    t=2 h                       0.816       0.765       0.861       0.715
    t=4--6 h                    0.824       0.983       0.746       0.586

ACE, angiotensin converting enzyme; BMI, body mass index, BMI, weight (kg)/(height)^2^ (m^2^); CAD, coronary artery disease; CT, computed tomography; CA, coronary angiography; ARB, angiotensin receptor blockers; N/L, neutrophils to lymphocytes ratio; P/L, platelets to lymphocytes ratio; CRP, C-reactive protein; FIRI, (glucose × insulin)/25; TAC, total anti-oxidant activity; GSH, glutathione; TBARS, thio-barbituric acid reactive species.

###### 

Effect of CM administration on renal functions parameters and oxidative stress markers in the study population.

  A, CAD group (early CIN patients excluded)                                                                                                                                                                                                                                                                                                                                                            
  -------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------------
  t=0                                          0.806±0.117                                                39.6±12.4                                                0.588±0.482                                              0.905±0.128                                                3.58±1.31                                                174±30.1                                                1.26±0.412
  t=1 h                                        0.828±0.192                                                38.4±14.8                                                0.63±0.493                                               0.956±0.114^[b](#tfn7-br-0-0-1071){ref-type="table-fn"}^   3.46±1.26                                                179±45.1                                                0.840±0.228^[b](#tfn7-br-0-0-1071){ref-type="table-fn"}^
  t=4--6 h                                     0.876±0.222                                                34.1±11.4^[a](#tfn6-br-0-0-1071){ref-type="table-fn"}^   1.45±1.02^[c](#tfn8-br-0-0-1071){ref-type="table-fn"}^   0.926±0.105                                                4.71±1.94^[a](#tfn6-br-0-0-1071){ref-type="table-fn"}^   163±35.1^[a](#tfn6-br-0-0-1071){ref-type="table-fn"}^   0.889± 0.248^[a](#tfn6-br-0-0-1071){ref-type="table-fn"}^
                                                                                                                                                                                                                                                                                                                                                                                                        
  **B, Control group**                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                        
  **Sampling time**                            **Creatinine (mg/dl)**                                     **Urea (mg/dl)**                                         **GSH (µmol/g Hb)**                                      **TAC (mmol DPPH/L plasma)**                               **TBARS (µmol/l)**                                       **Catalase (U/mg Hb)**                                  **Carbonyls (nmol/mg protein)**
                                                                                                                                                                                                                                                                                                                                                                                                        
  t=0                                          1.06±0.190                                                 42.8±23.2                                                1.91± 0.807                                              0.956± 0.150                                               7.32± 1.34                                               192± 67.8                                               0.793± 0.141
  t=1 h                                        1.04±0.151                                                 49.6±24.0                                                2.01±0.43                                                0.945±0.157                                                7.81±1.88                                                193±94.1                                                0.794± 0.128
  t=5--10 h                                    0.839±0.242^[b](#tfn7-br-0-0-1071){ref-type="table-fn"}^   39.8±14.9                                                2.13±1.14                                                0.933±0.161                                                8.06±3.26                                                223±108                                                 0.785±0.180

Statistical significance compared to t=0

P\<0.05

P\<0.01

P\<0.001. CAD, coronary artery disease; CIN, contrast induced nephropathy; CM, contrast medium; GSH, glutathione; TAC, total anti-oxidant activity; TBARS, thio-barbituric acid reactive species.
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